SCYNEXIS, Inc. (SCYX) Stock Analysis & Investment Frameworks
SCYNEXIS, Inc. (SCYX) stock analysis on Invetso. Review SCYNEXIS, Inc.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
SCYNEXIS, Inc. Company Overview
- Exchange: NASDAQ
- Sector: Healthcare
- Industry: Medical - Pharmaceuticals
- Country: US
SCYNEXIS, Inc. Key Financial Metrics
- Market Cap: $23.90M
- Revenue: $20.60M
- ROE: -21.10%
- ROIC: -32.44%
- Dividend Yield: N/A
About SCYNEXIS, Inc.
SCYNEXIS, Inc. is a biotechnology company, which engages in the development of novel oral and intravenous triterpenoid antifungal for the treatment of several fungal infections, including vulvovaginal candidiasis, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections. The company was founded by Scot Kevin Huber, Terry Eugene Marquardt, Pierre Bernard Jacques Monnet, Russell J. Outcalt, and Yves Joseph Ribeill on November 4, 1999 and is headquartered in Jersey City, NJ.
SCYNEXIS, Inc. Investment Frameworks
Invetso analyzes SCYNEXIS, Inc. (SCYX) across the following frameworks:
- SCYNEXIS, Inc. 10Y Growth Potential
- SCYNEXIS, Inc. Scenario Analysis
- SCYNEXIS, Inc. Risks & Opportunities
- SCYNEXIS, Inc. Economic Moat
- SCYNEXIS, Inc. Business Model
- SCYNEXIS, Inc. Management
- SCYNEXIS, Inc. SWOT Analysis
- SCYNEXIS, Inc. Porter's 5 Forces
- SCYNEXIS, Inc. PESTLE Analysis
- SCYNEXIS, Inc. ESG Analysis